Drug
Setidegrasib
Setidegrasib: highest development phase Phase 3, developed by Astellas. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| Setidegrasib NCT07409272 | Phase 3 | Pancreatic Cancer |
| Setidegrasib NCT07566052 | Phase 3 | Non-small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Setidegrasib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.